On May 27, 2025 GI Innovation (Co-CEOs Byung-Gun Lee and Jun-Ho Hong) reported that it has signed a Memorandum of Understanding (MOU) with Panolos Bioscience (CEO Hye-Seong Lim) for joint research on developing next-generation multi-target therapies (Press release, Panolos Bioscience, MAY 27, 2024, View Source [SID1234656260]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The signing ceremony, held at GI Innovation’s headquarters, was attended by key executives from both companies, including Myung-Ho Jang, CSO of GI Innovation, and Hye-Seong Lim, CEO, and Hak-Rim Ju, COO of Panolos.
Under this MOU, the two companies plan to cooperate on △mutual technology exchange, △preclinical and clinical development, △global technology transfer, and △national R&D project selection.
GI Innovation specializes in the development of immuno-oncology drugs based on its dual fusion protein platform, GI-SMART. The company is currently conducting clinical trials for immuno-oncology and allergy treatments using this platform. Panolos Bioscience, a leading company in structure-based protein drug development, is conducting clinical trials for PB101, which enhances the anti-tumor immune system and normalizes blood vessels. Both companies expect to achieve various synergies based on their proprietary protein development technologies.
Junho-Hong, Co-CEO of GI Innovation, stated, "We anticipate strong synergies from combining Panolos’ αART platform with GI Innovation’s GI-SMART platform through this agreement. We hope this MOU will further promote research exchanges among domestic bio-ventures."
Hye-Seong Lim, CEO of Panolos, commented, "This joint research MOU is expected to be a crucial turning point in combining the expertise and capabilities of both companies to develop new treatment methods and innovative solutions."
Meanwhile, GI Innovation is actively conducting clinical trials for the immuno-oncology drugs GI-101 and GI-102 in Korea and the US, and for the allergy treatment GI-301 in Korea. Panolos is developing PB101, currently in clinical trials, as well as dual-target anti-cancer drug PB203 and triple-target anti-cancer drug PB301 based on PB101.